Urinary Tract Adenocarcinoma — knowledge graph · CancerIndex

Knowledge graph · Cancer

Urinary Tract Adenocarcinoma

subtype

Identifier: CI-CAN-00007013
Entity page: /cancer/urinary-tract-adenocarcinoma ↗
Edges: 24

Neighbours: 15 drugs9 trials
Drawn: 24 of 24 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Urinary Tract Adenocarcinoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 15
→ investigated in trials for	Enfortumab Vedotinadc 2 trials (2 active) · roll-up of the cancer and its descendants	—	—	Urinary Tract Adenocarcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Ipilimumabmonoclonal antibody 2 trials (2 active) · roll-up of the cancer and its descendants

Urinary Tract Adenocarcinoma studied in …STUDIED_INderived9 of 9
→ studied in	NCT03866382Phase 2 · recruiting Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors · condition mapped CURATED_BROADER · 9 trials mapped (4 active)	—	—	Bladder Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06041503Phase 2 · recruiting Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE) · condition mapped ALIAS · 9 trials mapped (4 active)	—	—	Bladder Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05756569Phase 2 · recruiting Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology · condition mapped ONTOLOGY_EXACT · 9 trials mapped (4 active)	—	—	Urachal Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02834013Phase 2 · active not recruiting Nivolumab and Ipilimumab in Treating Patients With Rare Tumors · condition mapped CURATED_BROADER · 9 trials mapped (4 active)	—	—	Bladder Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03912818Phase 2 · terminated Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer · condition mapped CURATED_BROADER · 9 trials mapped (4 active)	—	—	Bladder Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03430895Phase 2 · completed Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract · condition mapped ALIAS · 9 trials mapped (4 active)	—	—	Bladder Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT00072137Phase 1 · terminated Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy · condition mapped CURATED_BROADER · 9 trials mapped (4 active)	—	—	Bladder Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT00407485Phase 2 · completed VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium · condition mapped ALIAS · 9 trials mapped (4 active)	—	—	Bladder Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT00112905Phase 2 · terminated Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium · condition mapped ALIAS · 9 trials mapped (4 active)	—	—	Bladder Adenocarcinoma	1	Observed	clinicaltrials	graph →